WIPO’s Standing Committee on the Law of Patents (SCP)
Access to Medicine
Special 301
The USTR’s Special 301 Report has been issued every year beginning in 1989. The Executive Summary of the 2009 report says: The “Special 301” Report is an annual review of the global state of intellectual property rights (IPR) protection and… Continue Reading
2010 Fabrazyme March-In Request
More on Fabry here: https://keionline.org/fabry NIH rejects Fabrazyme March-In Petition December 7, 2010. Press release from Fabry patients: DHHS denies patient’s march-in request to end Genzyme’s rationing of treatment for Fabry Disease citing that FDA rules block manufactures from supplying… Continue Reading
KEI Work on chimeric antigen receptor technologies
You also can search for our most recent work on chimeric antigen receptor T-cell (CAR T) technologies using our tags here, or via our general search engine here. NIH CRADAs involving antigen receptor technologies. See this sheet. CAR patent litigation… Continue Reading
The 2016-2017 Army proposal for exclusive patent license to Sanofi for Zika vaccine
(More on government funded inventions here: https://keionline.org/government-funded-inventions) On December 9, 2016, the U.S. Army announced its intent to grant an exclusive license to Sanofi on patents for a U.S. Army-developed Zika vaccine. KEI and various other non-profit groups have filed… Continue Reading
Licensing NIH owned patents and data, including KEI comments on proposed exclusive licenses
(More on government funded inventions here) 2015 2015: Virotas Biopharmaceuticals. KEI and Public Citizen ask NIH for safeguards in license for HCV patents, April 14, 2015. 2015: NIH refuses to give information about principals in company seeking exclusive license to… Continue Reading
EB142: KEI statement on WHO’s decision on the Global strategy and plan of action on public health, innovation and intellectual property
After lengthy negotiations, on Friday, 26 January 2018 the World Health Organization’s Executive Board approved a decision to reinvigorate the Organization’s work program on innovation and access to medicines. Here are two quotes from KEI on the decision: James Love,… Continue Reading
EB142: KEI statement on the Global Strategy and plan of action on public health, innovation and IP
The World Health Organization’s (WHO) Executive Board is expected to discuss agenda item 3.7 on the Global strategy and plan of action on public health, innovation and intellectual property either on Wednesday, 24 January 2018 or Thursday, 25 January 2018.… Continue Reading
EB142: KEI statement on Addressing the global shortage of, and access to, medicines and vaccines
On Wednesday, 24 January 2018, the World Health Organization’s (WHO) Executive Board is expected to discuss agenda item 3.6 on Addressing the global shortage of, and access to, medicines and vaccines. Non-state actors in official relations with the WHO are… Continue Reading
PhRMA letter on Colombia Resolution 5246
On January 15, 2018, PhRMA provided comments on the Colombian Resolution 5246, a public interest declaration for several drugs for the hepatitis c virus (HCV). A copy of the PhRMA letter is attached below. It is a combination of complaints… Continue Reading